Providence Health & Services

New datma Patent Simplifies the Integration of Pathology Data into datma.FED Platform BEAVERTON, Ore., Dec. 16, 2024 /PRNewswire/ -- datma, a leading provider of federated Real-World Data platform and related analytical tools, today announced its patent-protected pathology data labeling system will be part of its datma.FED platform, improving the preparation and usability of pathology data for federated analysis. The datma patent for the "System and Method for Automatic Labeling of Pathology Images" was developed in collaboration with Providence Health & Services, a not-for-profit health system serving the Western U.S. Continue Reading "This patent exemplifies datma's mission to address critical challenges in healthcare data sharing," said Noah Nasser, CEO of datma. "Automating pathology data labeling not only reduces the operational burden on healthcare systems but also enhances the quality and usability of data for use in real-world evidence generation efforts. This technology represents a key step to empower healthcare organizations in unlocking the full potential of their data." This patent exemplifies datma's mission to address critical challenges in healthcare data sharing... Post this datma's pathology data labeling system, as part of the datma.FED platform, is designed to address a persistent challenge in healthcare data preparation by automating the labeling of pathology images to improve accuracy, efficiency, and integration into research frameworks. datma.FED facilitates secure privacy-first data-sharing between healthcare data custodians, such as health systems and laboratories, and data consumers, including pharmaceutical companies and research organizations. Addressing Challenges in Healthcare Data Pathology images, which are often unstructured and challenging to standardize, represent a wealth of untapped potential for precision medicine and research. Traditionally, manual labeling of pathology images has been a resource intensive process prone to inconsistencies, limiting their usability. datma's automated labeling technology overcomes these barriers by ensuring accuracy and efficiency while preserving critical data attributes. By streamlining the labeling process, the system simplifies the integration of pathology data into secure data-sharing frameworks. This not only accelerates access to actionable insights for data consumers but also enhances the value and readiness of datasets contributed by data custodians. Supporting Federated Networks and Precision Medicine The automated labeling system aligns directly with datma's broader vision of enabling healthcare organizations to securely and efficiently share data while maintaining privacy and control. The patented system contributes to federated networks, where data remains decentralized and insights are aggregated without compromising patient privacy. By addressing data usability challenges, the new technology facilitates a seamless exchange of insights that can advance precision medicine, research, and innovation across the healthcare ecosystem. For more information about datma, please visit About datma datma is a leading provider of federated Real-World Data platform and related tools for analysis and visualization. datma's mission is to empower healthcare organizations to optimize their data assets, drive innovation, and improve patient outcomes through advanced data storage, AI-enabled data harmonization, and federated query and workflow technology. Headquartered in Oregon, the company is at the forefront of transforming how healthcare data is shared, monetized, and applied by enabling secure collaboration between data custodians and data consumers. By facilitating the analysis of rich, decentralized datasets without compromising privacy, datma enables health systems and reference laboratories to create secondary revenue streams and invest in innovation, while empowering data consumers with insights that may lead to new discoveries, greater access, and enhance clinical practice. For more information, visit Media Contact: Vikki Herrera Oak Street Communications [email protected] SOURCE datma, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN FRANCISCO & MONTREAL--( BUSINESS WIRE )--Nomic Bio Inc. (Nomic), a proteomics company with the highest-throughput platform for multiplexed protein quantification, and the Parker Institute for Cancer Immunotherapy (PICI), a collaborative consortium of the world’s leading immuno-oncology experts, today announced a research collaboration to quantify circulating protein biomarkers that are associated with patient responses to immunotherapy across cancer types. Under the collaboration, Nomic will profile blood samples from PICI’s RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) cohort, a prospective longitudinal study of 1,070 patients receiving standard-of-care immune checkpoint inhibitor (ICI) treatment regimens in 52 community hospitals across the United States. The testing, which will be conducted with Nomic’s nELISA platform, will provide parallel quantification of hundreds of proteins related to cancer and immune cell responses. The results will assess the levels of inflammatory and cancer-related proteins and explore their association with patient response to therapy, survival rates, and likelihood of developing immune-related adverse events. “By characterizing the soluble signaling molecules of our longitudinal patient samples, we aim to elucidate the communication pathways among immune cells in response to disease states and treatments,” said Tarak Mody, PhD, chief business officer at PICI. “The data from this mission-focused collaboration, along with other omics-data as part of the RADIOHEAD program, will enhance our understanding of treatment resistance and accelerate advancements in precision medicine to improve patient care.” This project will benefit from Nomic's revolutionary nELISA platform which provides industry-leading specificity and delivers absolute quantification of hundreds of key protein targets. These advancements combined with unparalleled throughput have already established Nomic as a leading proteomics solution provider in drug discovery. “We are excited to work with PICI to help elucidate how cancer patients respond to immunotherapy, as it becomes a first-line treatment option across an increasing number of cancer types,” said Milad Dagher, CEO and Co-Founder of Nomic. “Since its inception, the raison d’être of Nomic has been to empower scientists with the data they need to improve patients’ lives. This collaboration is a great opportunity for us to apply our nELISA technology to a project that can eventually help healthcare providers make more informed decisions about life-saving immunotherapies.” Nomic and PICI intend to begin publishing data generated by the study in early 2025. About Nomic At Nomic, we are making protein profiling broadly accessible. At the heart of our platform is the nELISA™, a proprietary technology that enables massive multiplexing with true flexibility, full quantification, and unmatched cost-efficiency. Nomic has developed the most comprehensive solution for inflammation research that allows for the high-throughput quantification of hundreds of secreted proteins. Nomic is rapidly expanding its biological footprint to cover proteins across the entire proteome, unlocking new possibilities for diverse applications, uses cases, and disease areas. For more information, visit nomic.bio and follow the company on LinkedIn. About the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, with an additional $125 million commitment announced in 2024, the San Francisco-based nonprofit is an unprecedented collaboration between the country’s leading immunotherapy researchers and cancer centers. PICI Network research institutions include Stanford Medicine; the University of California, Los Angeles; the University of California, San Francisco; the University of Pennsylvania; Dana-Farber Cancer Institute; Gladstone Institutes; and Weill Cornell Medicine. PICI also supports top researchers at other institutions, including The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City of Hope, Fred Hutchinson Cancer Research Center, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology and Washington University School of Medicine in St. Louis. By forging alliances with academic, industry and nonprofit partners, PICI makes big bets on bold research to fulfill its mission: to accelerate the development of breakthrough immunotherapies to turn all cancers into curable diseases. Find out more at parkerici.org and follow us on LinkedIn , X (formerly Twitter) @parkerici , and on Spotify and Apple Podcasts. About RADIOHEAD The RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients Interrogated by Harmonized Molecular Datasets) program is a pan-tumor, prospective cohort study of 1000+ immunotherapy naive individuals on standard of care immune checkpoint inhibitor (CPI) treatment regimens. This study captured a comprehensive profile of each participant by collecting blood samples and clinical features at pretreatment, early on-treatment, and late timepoints from 52 community oncology clinics across the United States. If participants experienced immune-related adverse events, additional samples were collected upon presentation and in follow-up visits. In all, over 3700 longitudinal samples were collected, with a focus on major IO indications such as non-small cell lung cancer (~1400 samples) and malignant melanoma (~500 samples). Pairing comprehensive multi-omic profiling of these longitudinal samples with associated demographic and clinical outcomes provides an opportunity to identify clinically actionable mechanisms for CPI resistance and adverse events, discover targets for combination therapies and post-CPI treatment, and inform system biology approaches to elucidate disease pathways.

SAN FRANCISCO--( BUSINESS WIRE )--The Parker Institute for Cancer Immunotherapy (PICI) today announced the appointments of Ansu Satpathy, MD, PhD, Julia Carnevale, MD, and Saar Gill, MBBS, PhD, FRACP, as Co-Directors of the PICI Centers at Stanford Medicine, University of California, San Francisco, and the University of Pennsylvania, respectively. These appointments reflect PICI's strategy to leverage leaders with expertise in translating scientific discoveries into innovative cancer immunotherapies, accelerating the development of breakthrough treatments through collaboration. The new Co-Directors are distinguished leaders in cancer immunotherapy research. Dr. Satpathy, a longstanding PICI Investigator and former Parker Bridge Scholar, has made significant advances in T cell immunotherapies and genomics. Dr. Carnevale has pioneered innovative approaches in T cell engineering and large-scale CRISPR screening. Dr. Gill is known for his numerous contributions to cellular therapy and genetic engineering for blood cancers. Importantly, these leaders bring extensive expertise at translating scientific discoveries into new technologies and treatments, as well as building the companies that will deliver them to patients. Dr. Satpathy has co-founded biotech companies including Cartography Biosciences and Immunai, which are applying advanced genomics to enhance immunotherapy development. Dr. Gill has launched Carisma Therapeutics and Interius Biotherapeutics, moving novel cell therapies from lab to clinic. Dr. Carnevale’s patented CRISPR screening method is propelling the creation of next-generation cell therapies, laying the groundwork for future biotech ventures. " In Drs. Satpathy, Carnevale and Gill, we have leaders who bridge the gap between scientific discovery and advancing new treatments to patients," said PICI Chief Scientific Officer John Connolly, PhD. " Each is a leading expert in their field, with a shared passion for advancing cancer immunotherapy and a commitment to collaborating across institutions to accelerate the development of breakthrough immune therapies." At Stanford Medicine, Dr. Satpathy joins Crystal Mackall, MD, Director of the PICI Center at Stanford Medicine, and Co-Director Mark Davis, PhD, in site leadership. " Ansu brings a rare combination of scientific insight and translational expertise to his new role as Co-Director of our PICI Center," said Dr. Mackall. " His groundbreaking work in immunogenomics, coupled with his success in launching multiple biotechnology ventures, demonstrates his ability to transform complex biological concepts into viable clinical strategies. This blend of scientific rigor and practical application is essential for accelerating our progress in cancer immunotherapy." Dr. Carnevale joins the leadership of the PICI Center at UCSF, partnering with Center Director Kole Roybal, PhD. She succeeds Lawrence Fong, MD, who has joined the Fred Hutchinson Cancer Center in Seattle as Scientific Director of the Immunotherapy Integrated Research Center (IIRC). PICI thanks Dr. Fong for his leadership and contributions to the PICI Center at UCSF. " Julia's pioneering work in CRISPR-based T cell engineering brings a unique and powerful skillset to our team," said Dr. Roybal. " As a physician-scientist, she's the ideal clinical counterpart to our research efforts, bridging bench discoveries with therapeutic applications. Her leadership will be key in translating our advanced engineered immune cell therapies from the lab to patients." Rounding out the trio of appointments, at Penn, Dr. Gill joins Carl June, MD, Director of the PICI Center at the University of Pennsylvania and E. John Wherry, PhD, Center Co-Director. " Saar's exceptional expertise in translational research, combined with his novel insights from regenerative medicine, will undoubtedly propel our immunotherapy efforts at the PICI Center. I look forward to our continued scientific partnership in advancing transformative cancer treatment modalities," said Dr. June. Learn more about the new Co-Directors by visiting the PICI website . About the Parker Institute for Cancer Immunotherapy The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, with an additional $125 million commitment announced in 2024, the San Francisco-based nonprofit is an unprecedented collaboration between the country’s leading immunotherapy researchers and cancer centers. PICI Network research institutions include Stanford Medicine; the University of California, Los Angeles; the University of California, San Francisco; the University of Pennsylvania; Dana-Farber Cancer Institute; Gladstone Institutes; and Weill Cornell Medicine. PICI also supports top researchers at other institutions, including The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, City of Hope, Fred Hutchinson Cancer Research Center, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology and Washington University School of Medicine in St. Louis. By forging alliances with academic, industry and nonprofit partners, PICI makes big bets on bold research to fulfill its mission: to accelerate the development of breakthrough immunotherapies to turn all cancers into curable diseases. Find out more at parkerici.org and follow us on LinkedIn , X , Apple Podcasts and Spotify.